Metyrosine

Chronic Pheochromocytoma

Chronic Pheochromocytoma Indicated for treatment of patients with pheochromocytoma for: 1) preoperative preparation for surgery; 2) management when surgery is contraindicated; and 3) chronic treatment with malignant pheochromocytoma Initial: 250 mg PO q6hr; may increase by 250-500 mg/day, not to exceed 4 g/day Maintenance: Typically 2-3 g/day divided q6hr

Hypersensitivity to metyrosine

Additive sedative effects w/ alcohol and other CNS depressants Take enough fluid to prevent crystalluria Use caution in hepatic or renal impairment Not recommended for essential HTN

C Pregnancy Category: C Lactation: not known if excreted into breast milk, use caution

>10% Sedation (>20%) 1-10% Diarrhea (10%) Exrapyramidal Symptoms (10%) Frequency Not Defined Fatigue Headache Psychic Disturbances Galactorrhea Sexual dysfunction Nausea Vomiting Xerostomia Nasal stuffiness Dysuria Crystalluria

Inhibits synthesis of endogenous catecholamines by inhibiting tyrosine hydroxylase